Seres Therapeutics issues shares to former landlord to settle lease termination debt

Seres Therapeutics filed a prospectus supplement dated July 31, 2026 covering an offering of 103,520 shares of common stock to BMR-Sidney Research Campus LLC. The shares are being offered pursuant to a stock issuance agreement dated July 31, 2026 between Seres and BMR-Sidney.¹ The offering price of $4.83 per share matches the closing price of Seres common stock on Nasdaq on that date.¹

The stock issuance is structured as part of the payment Seres owes BMR-Sidney under a Third Amendment to Lease and Termination Agreement, also dated July 31, 2026.¹ BMR-Sidney had served as Seres's landlord under a lease agreement dated November 11, 2015, as amended, which is being terminated under this new agreement.¹ The filing states that BMR-Sidney is not an affiliate of the company.¹

Seres said the issuance is not being made for capital-raising purposes but rather represents a portion of the total amount owed to BMR-Sidney in connection with terminating the Sidney Research Campus lease.¹ The total value of the shares offered is $500,001.60.¹ Seres will not receive any proceeds from the offering.¹

No underwriting discounts, commissions or other compensation will be paid, and no underwriter, broker, dealer or agent is participating in the transaction.¹ BMR-Sidney faces no lock-up period and can sell the shares immediately after they are issued, according to the filing.

On dilution, Seres said its as-adjusted net tangible book value as of March 31, 2026 would be about $26.5 million, or approximately $2.73 per share, after the offering, representing a $0.03 per share decrease for existing stockholders and $2.10 per share of dilution to BMR-Sidney.¹ Seres common stock trades on Nasdaq under "MCRB," and last closed at $5.03 per share on August 3, 2026.¹